Cancer Treatment Reviews
Volume 38, Issue 1 , Pages 3-26 , February 2012

Cytostatic drugs in infants: A review on pharmacokinetic data in infants

  • Hendrik van den Berg

      Affiliations

    • Department of Pediatric Oncology, Emma Children Hospital – Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    • Medicines Evaluation Board, The Hague, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Department of Paediatric Oncology, Emma Children Hospital Academic Medical Centre, University of Amsterdam, Room F8-242, P.O. Box 22700, 1100 DD Amsterdam, The Netherlands. Tel.: +31 20 5663050; fax: +31 20 6912231.
    • ,
  • John N. van den Anker

      Affiliations

    • Division of Pediatric Clinical Pharmacology, Children’s National Medical Center, Washington, DC, USA
    • Departments of Pediatrics, Pharmacology, and Physiology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
    • Department of Pediatrics, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands
    • ,
  • Jos H. Beijnen

      Affiliations

    • The Netherlands Cancer Institute, Slotervaart Hospital, Amsterdam, The Netherlands

Received 11 January 2011 ,Revised 21 March 2011 ,Accepted 24 March 2011.

References 

  1. Woods WG, O’Leary M, Nesbit ME. Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia. J Pediatr. 1981;98:642–645
  2. Allen JC. The effects of cancer therapy on the nervous system. J Pediatr. 1978;93:903–909
  3. Reaman G, Zeltzer P, Bleyer WA, Amendola B, Level C, Sather H, et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children’s Cancer Study Group. J Clin Oncol. 1985;3:1513–1521
  4. Jones B, Breslow NE, Takashima J. Toxic deaths in the Second National Wilms’ Tumor Study. J Clin Oncol. 1984;2:1028–1033
  5. Arndt C, Hawkins D, Anderson JR, Breitfeld P, Womer R, Meyer W. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol. 2004;22:1894–1901
  6. Reaman GH. Special considerations for the infant with cancer. In:  Pizzo PA,  Poplack DG editor. Pediatric Oncology. Philadelphia, USA: J.B.Lippincott; 1989;p. 263–274
  7. Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos. 1995;23:1110–1116
  8. Pieters R, Schrappe M, De LP, Hann I, De RG, Felice M, et al. A treatment protocol for infants younger than 1year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370:240–250
  9. van der Linden MH, Valsecchi MG, De LP, Moricke A, Janka G, Leblanc TM, et al. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood. 2009;114:3764–3768
  10. Hempel G, Relling MV, De RG, Stary J, De LP, Valsecchi MG, et al. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer. 2010;54:355–360
  11. Adamson PC. It’s not easy being small. Pediatr Blood Cancer. 2010;54:341–343
  12. breitkreuz J, Buckham J, Fischer R, Postges R, Boos J. Comparative in vitro studies on different 6-mercaptopurine formulations for use in children. Paed Perinat Drug Ther. 2007;8:31–39
  13. HUANG NN, HIGH RH. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J Pediatr. 1953;42:657–658
  14. Agunod M, Yamaguchi N, Lopez R, Luhby AL, Glass GB. Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am J Dig Dis. 1969;14:400–414
  15. Kearns GL, bdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–1167
  16. Gupta M, Brans YW. Gastric retention in neonates. Pediatrics. 1978;62:26–29
  17. Ittmann PI, Amarnath R, Berseth CL. Maturation of antroduodenal motor activity in preterm and term infants. Dig Dis Sci. 1992;37:14–19
  18. Huang CT, Rodriguez JT, Woodward WE, Nichols BL. Comparison of patterns of fecal bile acid and neutral sterol between children and adults. Am J Clin Nutr. 1976;29:1196–1203
  19. POLEY JR, DOWER JC, OWEN CA, STICKLER GB. Bile acids in infants and children. J Lab Clin Med. 1964;63:838–846
  20. Weaver LT, Austin S, Cole TJ. Small intestinal length: a factor essential for gut adaptation. Gut. 1991;32:1321–1323
  21. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45:931–956
  22. Linday L, Dobkin JF, Wang TC, Butler VP, Saha JR, Lindenbaum J. Digoxin inactivation by the gut flora in infancy and childhood. Pediatrics. 1987;79:544–548
  23. Stahlberg MR, Hietanen E, Maki M. Mucosal biotransformation rates in the small intestine of children. Gut. 1988;29:1058–1063
  24. Fakhoury M, Litalien C, Medard Y, Cave H, Ezzahir N, Peuchmaur M, et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos. 2005;33:1603–1607
  25. Johnson TN, Tanner MS, Taylor CJ, Tucker GT. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol. 2001;51:451–460
  26. Reed MD, Besunder JB. Developmental pharmacology: ontogenic basis of drug disposition. Pediatr Clin North Am. 1989;36:1053–1074
  27. Friis-Hansen B. Water distribution in the foetus and newborn infant. Acta Paediatr Scand Suppl. 1983;305:7–11
  28. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther. 2008;118:250–267
  29. Blanco JG, Harrison PL, Evans WE, Relling MV. Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos. 2000;28:379–382
  30. Takahashi H, Ishikawa S, Nomoto S, Nishigaki Y, Ando F, Kashima T, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther. 2000;68:541–555
  31. Miyagi SJ, Collier AC. Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4. Drug Metab Dispos. 2007;35:1587–1592
  32. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006;25:1679–1691
  33. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther. 2002;300:355–360
  34. McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther. 2002;300:361–366
  35. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, et al. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst. 1990;82:1333–1339
  36. Goria-Gatti L, Iannone A, Tomasi A, Poli G, Albano E. In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin-trapping study. Carcinogenesis. 1992;13:799–805
  37. Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem. 1998;251:893–898
  38. Blake MJ, Abdel-Rahman SM, Pearce RE, Leeder JS, Kearns GL. Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res. 2006;60:717–723
  39. Le Guennec JC, Billon B. Delay in caffeine elimination in breast-fed infants. Pediatrics. 1987;79:264–268
  40. van Schaik RH. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs. 2005;23:513–522
  41. Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 2005;6:780–789
  42. Kawashiro T, Yamashita K, Zhao XJ, Koyama E, Tani M, Chiba K, et al. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998;286:1294–1300
  43. Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, et al. I. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics. 2007;17:731–742
  44. Hakkola J, Pasanen M, Pelkonen O, Hukkanen J, Evisalmi S, Anttila S, et al. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis. 1997;18:391–397
  45. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 2000;60:5074–5079
  46. Raunio H, Valtonen J, Honkakoski P, Lang MA, Stahlberg M, Kairaluoma MA, et al. Immunochemical detection of human liver cytochrome P450 forms related to phenobarbital-inducible forms in the mouse. Biochem Pharmacol. 1990;40:2503–2509
  47. Gu J, Su T, Chen Y, Zhang QY, Ding X. Expression of biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity. Toxicol Appl Pharmacol. 2000;165:158–162
  48. Crespi CL, Penman BW, Leakey JA, Arlotto MP, Stark A, Parkinson A, et al. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis. 1990;11:1293–1300
  49. Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, et al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res. 2000;6:4409–4415
  50. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44:1135–1164
  51. Croom EL, Stevens JC, Hines RN, Wallace AD, Hodgson E. Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem Pharmacol. 2009;78:184–190
  52. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 2003;3:53–61
  53. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol. 2000;59:961–972
  54. Jacobson PA, Green K, Birnbaum A, Remmel RP. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol. 2002;49:461–467
  55. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307:906–922
  56. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol. 1990;38:207–213
  57. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414–423
  58. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004;308:965–974
  59. Leff RD, Fischer LJ, Roberts RJ. Phenytoin metabolism in infants following intravenous and oral administration. Dev Pharmacol Ther. 1986;9:217–223
  60. Andrew M, Marzinotto V, Brooker LA, Adams M, Ginsberg J, Freedom R, et al. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost. 1994;71:265–269
  61. Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G, et al. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol. 2003;59:103–109
  62. Relling MV, Evans WE, Fonne-Pfister R, Meyer UA. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. Cancer Res. 1989;49:68–71
  63. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11:597–607
  64. Treluyer JM, Jacqz-Aigrain E, Alvarez F, Cresteil T. Expression of CYP2D6 in developing human liver. Eur J Biochem. 1991;202:583–588
  65. Endrizzi K, Fischer J, Klein K, Schwab M, Nussler A, Neuhaus P, et al. Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction. Anal Biochem. 2002;300:121–131
  66. Gaedigk A, Gaedigk R, Leeder JS. CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein?. Biochem Biophys Res Commun. 2005;336:1241–1250
  67. Vieira I, Pasanen M, Raunio H, Cresteil T. Expression of CYP2E1 in human lung and kidney during development and in full-term placenta: a differential methylation of the gene is involved in the regulation process. Pharmacol Toxicol. 1998;83:183–187
  68. Vieira I, Sonnier M, Cresteil T. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem. 1996;238:476–483
  69. Johnsrud EK, Koukouritaki SB, Divakaran K, Brunengraber LL, Hines RN, McCarver DG. Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther. 2003;307:402–407
  70. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology. 1995;104:1–8
  71. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000;10:373–388
  72. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther. 2003;307:573–582
  73. Yang HY, Lee QP, Rettie AE, Juchau MR. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol Pharmacol. 1994;46:922–928
  74. Chen H, Fantel AG, Juchau MR. Catalysis of the 4-hydroxylation of retinoic acids by cyp3a7 in human fetal hepatic tissues. Drug Metab Dispos. 2000;28:1051–1057
  75. Schuetz JD, Beach DL, Guzelian PS. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics. 1994;4:11–20
  76. Hakkola J, Raunio H, Purkunen R, Saarikoski S, Vahakangas K, Pelkonen O, et al. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol Neonate. 2001;80:193–201
  77. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37:485–505
  78. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383–391
  79. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001;11:773–779
  80. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver – evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 1997;247:625–634
  81. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics. 1998;8:391–401
  82. Kishi S, Yang W, Boureau B, Morand S, Das S, Chen P, et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood. 2004;103:67–72
  83. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther. 2005;106:357–387
  84. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res. 2002;51:236–243
  85. Smith M, Hopkinson DA, Harris H. Developmental changes and polymorphism in human alcohol dehydrogenase. Ann Hum Genet. 1971;34:251–271
  86. Smith M, Hopkinson DA, Harris H. Alcohol dehydrogenase isozymes in adult human stomach and liver: evidence for activity of the ADH 3 locus. Ann Hum Genet. 1972;35:243–253
  87. Estonius M, Svensson S, Hoog JO. Alcohol dehydrogenase in human tissues: localisation of transcripts coding for five classes of the enzyme. FEBS Lett. 1996;397:338–342
  88. Alnouti Y, Klaassen CD. Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice. Toxicol Sci. 2008;101:51–64
  89. Tsukamoto N, Chen J, Yoshida A. Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. Blood Cells Mol Dis. 1998;24:231–238
  90. Pacifici GM, Romiti P, Giuliani L, Rane A. Thiopurine methyltransferase in humans: development and tissue distribution. Dev Pharmacol Ther. 1991;17:16–23
  91. McLeod HL, Krynetski EY, Wilimas JA, Evans WE. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics. 1995;5:281–286
  92. Tayama Y, Miyake K, Sugihara K, Kitamura S, Kobayashi M, Morita S, et al. Developmental changes of aldehyde oxidase activity in young Japanese children. Clin Pharmacol Ther. 2007;81:567–572
  93. Nebert DW, Vasiliou V. Analysis of the glutathione S-transferase (GST) gene family. Hum Genomics. 2004;1:460–464
  94. Hayes JD, Pulford DJ, Ellis EM, McLeod R, James RF, Seidegard J, et al. Regulation of rat glutathione S-transferase A5 by cancer chemopreventive agents: mechanisms of inducible resistance to aflatoxin B1. Chem Biol Interact. 1998;111–112:51–67
  95. Pacifici GM, Rane A. Epoxide hydrolase in human fetal liver. Pharmacology. 1983;26:241–248
  96. Strange RC, Howie AF, Hume R, Matharoo B, Bell J, Hiley C, et al. The development expression of alpha-, mu- and pi-class glutathione S-transferases in human liver. Biochim Biophys Acta. 1989;993:186–190
  97. Pacifici GM, Franchi M, Giuliani L, Rane A. Development of the glucuronyltransferase and sulphotransferase towards 2-naphthol in human fetus. Dev Pharmacol Ther. 1989;14:108–114
  98. Duanmu Z, Weckle A, Koukouritaki SB, Hines RN, Falany JL, Falany CN, et al. Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre- and postnatal human liver. J Pharmacol Exp Ther. 2006;316:1310–1317
  99. Richard K, Hume R, Kaptein E, Stanley EL, Visser TJ, Coughtrie MW. Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain. J Clin Endocrinol Metab. 2001;86:2734–2742
  100. Stanley EL, Hume R, Coughtrie MW. Expression profiling of human fetal cytosolic sulfotransferases involved in steroid and thyroid hormone metabolism and in detoxification. Mol Cell Endocrinol. 2005;240:32–42
  101. Cappiello M, Giuliani L, Rane A, Pacifici GM. Dopamine sulphotransferase is better developed than p-nitrophenol sulphotransferase in the human fetus. Dev Pharmacol Ther. 1991;16:83–88
  102. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004;32:1201–1208
  103. Burchell B, Coughtrie M, Jackson M, Harding D, Fournel-Gigleux S, Leakey J, et al. Development of human liver UDP-glucuronosyltransferases. Dev Pharmacol Ther. 1989;13:70–77
  104. de Wildt SN, Kearns GL, Leeder JS, Van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet. 1999;36:439–452
  105. Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut. 2002;50:259–265
  106. Zaya MJ, Hines RN, Stevens JC. Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos. 2006;34:2097–2101
  107. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, et al. UGT1A1∗28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2:43–47
  108. Pacifici GM, Bencini C, Rane A. Acetyltransferase in humans: development and tissue distribution. Pharmacology. 1986;32:283–291
  109. Hook JB, Hewitt WR. Development of mechanisms for drug excretion. Am J Med. 1977;62:497–506
  110. Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev. 2003;55:667–686
  111. Siegel SE, Moran RG. Problems in the chemotherapy of cancer in the neonate. Am J Pediatr Hematol Oncol. 1981;3:287–296
  112. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol. 1992;41:1047–1055
  113. Gouyette A, Hartmann O, Pico JL. Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol. 1986;16:184–189
  114. Morris ME, Griener JC, Msall ME. N-acetylator variability in Down’s syndrome: characterization with caffeine. Clin Pharmacol Ther. 1989;46:359–366
  115. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, et al. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol. 1996;41:13–19
  116. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, et al. Cyclophosphamide metabolism in children. Cancer Res. 1995;55:803–809
  117. Yule SM, Price L, McMahon AD, Pearson AD, Boddy AV. Cyclophosphamide metabolism in children with non-Hodgkin’s lymphoma. Clin Cancer Res. 2004;10:455–460
  118. Carrier O, Pons G, Rey E, Richard MO, Moran C, Badoual J, et al. Maturation of caffeine metabolic pathways in infancy. Clin Pharmacol Ther. 1988;44:145–151
  119. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496–526
  120. Timm R, Kaiser R, Lotsch J, Heider U, Sezer O, Weisz K, et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J. 2005;5:365–373
  121. DeMichele A, Aplenc R, Botbyl J, Colligan T, Wray L, Klein-Cabral M, et al. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol. 2005;23:5552–5559
  122. Mahmood B, Daood MJ, Hart C, Hansen TW, Watchko JF. Ontogeny of P-glycoprotein in mouse intestine, liver, and kidney. J Investig Med. 2001;49:250–257
  123. Johnson DR, Guo GL, Klaassen CD. Expression of rat Multidrug Resistance Protein 2 (Mrp2) in male and female rats during normal and pregnenolone-16alpha-carbonitrile (PCN)-induced postnatal ontogeny. Toxicology. 2002;178:209–219
  124. Schiengold M, Schwantes L, Schwartsmann G, Chies JA, Nardi NB. Multidrug resistance gene expression during the murine ontogeny. Mech Ageing Dev. 2001;122:255–270
  125. Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S, et al. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res. 2005;11:3758–3765
  126. Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K, et al. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol. 2003;21:2481–2485
  127. McFadyen MC, Melvin WT, Murray GI. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther. 2004;3:363–371
  128. Juma FD, Rogers HJ, Trounce JR. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmacol. 1979;8:209–217
  129. D’Incalci M, Bolis G, Facchinetti T, Mangioni C, Morasca L, Morazzoni P, et al. Decreased half life of cyclophosphamide in patients under continual treatment. Eur J Cancer. 1979;15:7–10
  130. Schmidt R, Baumann F, Knupfer H, Brauckhoff M, Horn LC, Schonfelder M, et al. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. Br J Cancer. 2004;90:911–916
  131. Juma FD, Rogers HJ, Trounce JR. The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. Br J Clin Pharmacol. 1980;10:327–335
  132. Bruggemann SK, Kisro J, Wagner T. Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Cancer Res. 1997;57:2676–2680
  133. Lind MJ, McGown AT, Hadfield JA, Thatcher N, Crowther D, Fox BW. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol. 1989;38:1835–1840
  134. Dockham PA, Lee MO, Sladek NE. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol. 1992;43:2453–2469
  135. Ren S, Kalhorn TF, Slattery JT. Inhibition of human aldehyde dehydrogenase 1 by the 4-hydroxycyclophosphamide degradation product acrolein. Drug Metab Dispos. 1999;27:133–137
  136. Tew KD, Colvin OM, Jones RB. Clinical and high-dose alkylating agents. In:  Chabner B,  Longo DL editor. Cancer Chemotherapy & Biotherapy. Philadelphia, US: Lippincott Williams &Wilkins; 2010;p. 281–309
  137. Mouridsen HT, Jacobsen E. Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol (Copenh). 1975;36:409–414
  138. Groninger E, Proost JH, de Graaf SS. Pharmacokinetic studies in children with cancer. Crit Rev Oncol Hematol. 2004;52:173–197
  139. Tasso MJ, Boddy AV, Price L, Wyllie RA, Pearson AD, Idle JR. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol. 1992;30:207–211
  140. Yule SM, Hide TA, Cranney M, Simpson E, Barrett A. Low grade astrocytomas in the West of Scotland 1987–96: treatment, outcome, and cognitive functioning. Arch Dis Child. 2001;84:61–64
  141. McCune JS, Salinger DH, Vicini P, Oglesby C, Blough DK, Park JR. Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children’s Oncology Group. J Clin Pharmacol. 2009;49:88–102
  142. Creaven PJ, Allen LM, Alford DA, Cohen MH. Clinical pharmacology of isophosphamide. Clin Pharmacol Ther. 1974;16:77–86
  143. Kerbusch T, de KJ, Mathjt RA, Beijne JH. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach. Clin Pharmacokinet. 2001;40:615–625
  144. Brade WP, Herdrich K, Varini M. Ifosfamide–pharmacology, safety and therapeutic potential. Cancer Treat Rev. 1985;12:1–47
  145. Norpoth K. Studies on the metabolism of isopnosphamide (NSC-109724) in man. Cancer Treat Rep. 1976;60:437–443
  146. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 1993;53:5629–5637
  147. Kaijser GP, de KJ, Bult A, Underberg WJ, Beijnen JH. Pharmacokinetics of ifosfamide and some metabolites in children. Anticancer Res. 1998;18:1941–1949
  148. Kerbusch T, de KJ, Keizer HJ, van Putten JW, Groen HJ, Jansen RL, et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet. 2001;40:41–62
  149. Boddy AV, Cole M, Pearson AD, Idle JR. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol. 1995;36:53–60
  150. Prasad VK, Corlett SA, Abaasi K, Heney D, Lewis I, Chrystyn H. Ifosfamide enantiomers: pharmacokinetics in children. Cancer Chemother Pharmacol. 1994;34:447–449
  151. Corlett SA, Parker D, Chrystyn H. Pharmacokinetics of ifosfamide and its enantiomers following a single 1h intravenous infusion of the racemate in patients with small cell lung carcinoma. Br J Clin Pharmacol. 1995;39:452–455
  152. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989;7:126–131
  153. Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR. Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer. 1995;31A:785–790
  154. Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res. 1993;53:3758–3764
  155. Friedman HS, Averbuch SD, Kurtzberg J. Nonclassical Agents. In:  Chabner B,  Longo DL editor. Cancer Chemotherapy & Biotherapy. Philadelphia, US: Lippincott Williams &Wilkins; 2010;p. 310–331
  156. Hall J, Kataoka H, Stephenson C, Karran P. The contribution of O6-methylguanine and methylphosphotriesters to the cytotoxicity of alkylating agents in mammalian cells. Carcinogenesis. 1988;9:1587–1593
  157. Lunn JM, Harris AL. Cytotoxicity of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide. Br J Cancer. 1988;57:54–58
  158. Panetta JC, Kirstein MN, Gajjar A, Nair G, Fouladi M, Heideman RL, et al. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol. 2003;52:435–441
  159. Sardi I, Cetica V, Massimino M, Buccoliero AM, Giunti L, Genitori L, et al. Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. Oncol Rep. 2009;22:773–779
  160. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug–drug interaction. J Pharmacokinet Pharmacodyn. 2004;31:135–156
  161. Maanen MJ, Smeets CJ, Beijnen JH. Chemistry, pharmacology and pharmacokinetics of N,N′,N″-triethylenethiophosphoramide (ThioTEPA). Cancer Treat Rev. 2000;26:257–268
  162. Tew KD, Colvin OM, Jones RB. Clinical and high-dose alkylating agents. In:  Chabner B,  Longo DL editor. Cancer Chemotherapy & Biotherapy. Philadelphia, US: Lippincott Williams &Wilkins; 2010;p. 281–309
  163. Kletzel M, Kearns GL, Wells TG, Thompson HC. Pharmacokinetics of high dose thiotepa in children undergoing autologous bone marrow transplantation. Bone marrow transplant. 1992;10:171–175
  164. Kohn KW, Spears CL, Doty P. Inter-strand crosslinking of DNA by nitrogen mustard. J Mol Biol. 1966;19:266–288
  165. Ludlum DB, Kramer BS, Wang J, Fenselau C. Reaction of 1,3-bis(2-chloroethyl)-1-nitrosourea with synthetic polynucleotides. Biochemistry. 1975;14:5480–5485
  166. May HE, Kohlhepp SJ, Boose RB, Reed DJ. Synthesis and identification of products derived from the metabolism of the carcinostatic 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea by rat liver microsomes. Cancer Res. 1979;39:762–772
  167. Kramer RA. Cytochrome P-450-dependent formation of alkylating metabolites of the 2-chloroethylnitrosoureas MeCCNU and CCNU. Biochem Pharmacol. 1989;38:3185–3192
  168. Wheeler GP, Johnston TP, Bowdon BJ, McCaleb GS, Hill DL, Montgomery JA. Comparison of the properties of metabolites of CCNU. Biochem Pharmacol. 1977;26:2331–2336
  169. Kastrissios H, Chao NJ, Blaschke TF. Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. Cancer Chemother Pharmacol. 1996;38:425–430
  170. Begleiter A, Mowat M, Israels LG, Johnston JB. Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leuk Lymphoma. 1996;23:187–201
  171. Zwaveling J, Press RR, Bredius RG, van Derstraaten TR, den HJ, Bartelink IH, et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit. 2008;30:504–510
  172. Bartelink IH, Bredius RG, Belitser SV, Suttorp MM, Bierings M, Knibbe CA, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:231–241
  173. Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:307–314
  174. Dalle JH, Wall D, Theoret Y, Duval M, Shaw L, Larocque D, et al. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. Bone Marrow Transplant. 2003;32:647–651
  175. Bostrom B, Enockson K, Johnson A, Bruns A, Blazar B. Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. Pediatr Transplant. 2003;7(Suppl 3):12–18
  176. Hassan M, Fasth A, Gerritsen B, Haraldsson A, Syruckova Z, van den Berg H, et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant. 1996;18:843–850
  177. Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol. 1989;24:386–390
  178. Nakamura H, Sato T, Okada K, Miura G, Ariyoshi N, Nakazawa K, et al. Population pharmacokinetics of oral busulfan in young Japanese children before hematopoietic stem cell transplantation. Ther Drug Monit. 2008;30:75–83
  179. Vassal G, Michel G, Esperou H, Gentet JC, Valteau-Couanet D, Doz F, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008;61:113–123
  180. Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT. Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos. 1999;27:1466–1469
  181. Wall DA, Chan KW, Nieder ML, Hayashi RJ, Yeager AM, Kadota R, et al. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010;54:291–298
  182. Tattersall MH, Jarman M, Newlands ES, Holyhead L, Milstead RA, Weinberg A. Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer. 1978;14:507–513
  183. Davis TP, Peng YM, Goodman GE, Alberts DS. HPLC, MS, and pharmacokinetics of melphalan, bisantrene and 13-cis retinoic acid. J Chromatogr Sci. 1982;20:511–516
  184. Taha IA, Ahmad RA, Rogers DW, Pritchard J, Rogers HJ. Pharmacokinetics of melphalan in children following high-dose intravenous injection. Cancer Chemother Pharmacol. 1983;10:212–216
  185. Alberts DS, Chang SY, Chen HS, Moon TE, Evans TL, Furner RL, et al. Kinetics of intravenous melphalan. Clin Pharmacol Ther. 1979;26:73–80
  186. Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996;2:947–952
  187. Nath CE, Shaw PJ, Montgomery K, Earl JW. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol. 2007;64:151–164
  188. Nath CE, Shaw PJ, Montgomery K, Earl JW. Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. Br J Clin Pharmacol. 2005;59:314–324
  189. Ueda T, Matsuyama S, Yamauchi T, Kishi S, Fukushima T, Tsutani H, et al. Clinical pharmacology of intermediate and low-dose cytosine arabinoside (ara-C) therapy in patients with hematologic malignancies. Adv Exp Med Biol. 1998;431:647–651
  190. Koehl U, Hollatz G, Rohrbach E, Visschedyk K, Cinatl J, Kornhuber B, et al. Pharmacology of intracellular cytosine–arabinoside–5′-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes. Cancer Chemother Pharmacol. 2007;60:467–477
  191. Capizzi RL, Yang JL, Cheng E, Bjornsson T, Sahasrabudhe D, Tan RS, et al. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol. 1983;1:763–771
  192. Avramis VI, Weinberg KI, Sato JK, Lenarsky C, Willoughby ML, Coates TD, et al. Pharmacology studies of 1-beta-d-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. Cancer Res. 1989;49:241–247
  193. van Prooijen HC, Dekker AW, Punt K. The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse. Br J Haematol. 1984;57:291–299
  194. Periclou AP, Avramis VI. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. Cancer Chemother Pharmacol. 1996;39:42–50
  195. Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood. 2003;101:1270–1276
  196. Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children’s Cancer Group. Clin Cancer Res. 1998;4:45–52
  197. McLeod HL, Relling MV, Crom WR, Silverstein K, Groom S, Rodman JH, et al. Disposition of antineoplastic agents in the very young child. Br J Cancer Suppl. 1992;18:S23–S29
  198. Lund B, Kristjansen PE, Hansen HH. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev. 1993;19:45–55
  199. Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol. 1994;12:1527–1531
  200. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. 1990;50:4417–4422
  201. Gandhi V, Legha J, Chen F, Hertel LW, Plunkett W. Excision of 2′,2′-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res. 1996;56:4453–4459
  202. Iwasaki H, Huang P, Keating MJ, Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood. 1997;90:270–278
  203. Steinherz PG, Seibel NL, Ames MM, Avramis VI, Krailo MD, Liu-Mares W, et al. Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children’s Cancer Group. Leuk Lymphoma. 2002;43:1945–1950
  204. Reid JM, Qu W, Safgren SL, Ames MM, Krailo MD, Seibel NL, et al. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol. 2004;22:2445–2451
  205. Nieto Y, Aldaz A, Rifon J, Perez-Calvo J, Zafra A, Zufia L, et al. Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. Biol Blood Marrow Transplant. 2007;13:1324–1337
  206. Chu E, Drake JC, Boarman D, Baram J, Allegra CJ. Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells. J Biol Chem. 1990;265:8470–8478
  207. Lyons SD, Sant ME, Christopherson RI. Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia. J Biol Chem. 1990;265:11377–11381
  208. Borsi JD, Sagen E, Romslo I, Slordal L, Moe PJ. 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 1990;27:164–167
  209. Whitehead VM, Payment C, Cooley L, Lauer SJ, Mahoney DH, Shuster JJ, et al. The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia. 2001;15:1081–1088
  210. Graham ML, Shuster JJ, Kamen BA, Land VJ, Borowitz MJ, Camitta B, et al. Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: a pediatric oncology group study. Clin Cancer Res. 1996;2:331–337
  211. Paal K, Horvath J, Csaki C, Ferencz T, Schuler D, Borsi JD. Effect of etoposide on the pharmacokinetics of methotrexate in vivo. Anticancer Drugs. 1998;9:765–772
  212. Thompson PA, Murry DJ, Rosner GL, Lunagomez S, Blaney SM, Berg SL, et al. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007;59:847–853
  213. Murry DJ, Synold TW, Pui CH, Rodman JH. Renal function and methotrexate clearance in children with newly diagnosed leukemia. Pharmacotherapy. 1995;15:144–149
  214. Donelli MG, Zucchetti M, Robatto A, Perlangeli V, D’Incalci M, Masera G, et al. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med Pediatr Oncol. 1995;24:154–159
  215. Lonnerholm G, Valsecchi MG, De LP, Schrappe M, Hovi L, Campbell M, et al. Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009;52:596–601
  216. Ramakers-van Woerden NL, Pieters R, Rots MG, van Zantwijk CH, Noordhuis P, Beverloo HB, et al. Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance. Leukemia. 2002;16:949–951
  217. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res. 2004;10:4276s–4280s
  218. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57:1116–1123
  219. Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol. 1999;26:42–47
  220. Zhao R, Babani S, Gao F, Liu L, Goldman ID. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin Cancer Res. 2000;6:3687–3695
  221. Malempati S, Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M, et al. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children’s Oncology Group. J Clin Oncol. 2007;25:1505–1511
  222. Kato Y, Matsushita T, Uchida H, Egi S, Yokoyama T, Mohri K. Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of “first-pass” metabolism. Eur J Clin Pharmacol. 1992;42:619–622
  223. Zimm S, Collins JM, Riccardi R, O’Neill D, Narang PK, Chabner B, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?. N Engl J Med. 1983;308:1005–1009
  224. Zimm S, Collins JM, O’Neill D, Chabner BA, Poplack DG. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther. 1983;34:810–817
  225. Kato Y, Matsushita T, Chiba K, Hijiya N, Yokoyama T, Ishizaki T. Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia. J Pediatr. 1991;119:311–316
  226. Tidd DM, Paterson AR. Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 1974;34:733–737
  227. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance?. Br J Cancer. 1995;72:1004–1006
  228. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene. 2006;25:1629–1638
  229. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics. 1996;6:279–290
  230. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989;46:149–154
  231. Schmiegelow K, Forestier E, Kristinsson J, Soderhall S, Vettenranta K, Weinshilboum R, et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia. 2009;23:557–564
  232. Zimm S, Ettinger LJ, Holcenberg JS, Kamen BA, Vietti TJ, Belasco J, et al. Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res. 1985;45:1869–1873
  233. Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children’s cancer group and pediatric oncology branch study. Blood. 1998;92:3569–3577
  234. Lowe ES, Kitchen BJ, Erdmann G, Stork LC, Bostrom BC, Hutchinson R, et al. Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children’s Cancer Group study. Cancer Chemother Pharmacol. 2001;47:199–205
  235. Adamson PC, Poplack DG, Balis FM. The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. Leuk Res. 1994;18:805–810
  236. Pieters R, Huismans DR, Leyva A, Veerman AJ. Sensitivity to purine analogues in childhood leukemia assessed by the automated MTT-assay. Adv Exp Med Biol. 1989;253A:447–454
  237. Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol. 1998;42:266–272
  238. Stork LC, Matloub Y, Broxson E, La M, Yanofsky R, Sather H, et al. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children’s Oncology Group CCG-1952 clinical trial. Blood. 2010;115:2740–2748
  239. Josefine P, Britt-Marie F, Curt P, Henrik H, Marit H, Jukka K, et al. Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia. Anticancer Drugs. 2009;20:7–14
  240. Keyomarsi K, Moran RG. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res. 1986;46:5229–5235
  241. Patel R, Newman EM, Villacorte DG, Sato JK, Reaman GH, Finklestein JZ, et al. Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children’s Cancer Study Group. Cancer Res. 1991;51:4871–4875
  242. Pettitt AR. Mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br J Haematol. 2003;121:692–702
  243. Malspeis L, Grever MR, Staubus AE, Young D. Pharmacokinetics of 2-F-ara-A (9-beta-d-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Semin Oncol. 1990;17:18–32
  244. Sandoval A, Consoli U, Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res. 1996;2:1731–1741
  245. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41:93–103
  246. Avramis VI, Champagne J, Sato J, Krailo M, Ettinger LJ, Poplack DG, et al. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res. 1990;50:7226–7231
  247. Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther. 1991;49:239–268
  248. Chunduru SK, Appleman JR, Blakley RL. Activity of human DNA polymerases alpha and beta with 2-chloro-2′-deoxyadenosine 5′-triphosphate as a substrate and quantitative effects of incorporation on chain extension. Arch Biochem Biophys. 1993;302:19–30
  249. Hande KR. Purin Antimetabolites. In:  Chabner B,  Longo DL editor. Cancer Chemotherapy & Biotherapy. Philadelphia, US: Lippincott Williams &Wilkins; 2010;p. 212–236
  250. Kearns CM, Blakley RL, Santana VM, Crom WR. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res. 1994;54:1235–1239
  251. Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Behm FG, et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002;20:4217–4224
  252. Watanabe K, Williams EF, Law JS, West WL. Effects of vinca alkaloids on calcium-calmodulin regulated cyclic adenosine 3′,5′-monophosphatase phosphodiesterase activity from brain. Biochem Pharmacol. 1981;30:335–340
  253. Wilson L. Microtubules as drug receptors: pharmacological properties of microtubule protein. Ann NY Acad Sci. 1975;253:213–231
  254. Crossin KL, Carney DH. Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell. 1981;27:341–350
  255. Jordan MA, Himes RH, Wilson L. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 1985;45:2741–2747
  256. Bourgeois H, Vermorken J, Dark G, Jones A, Fumoleau P, Stupp R, et al. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. Cancer Chemother Pharmacol. 2007;60:407–413
  257. Bugat R, Variol P, Roche H, Fumoleau P, Robinet G, Senac I. The effects of food on the pharmacokinetic profile of oral vinorelbine. Cancer Chemother Pharmacol. 2002;50:285–290
  258. Johansen M, Kuttesch J, Bleyer WA, Krailo M, Ames M, Madden T. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children’s Oncology Group. Clin Cancer Res. 2006;12:516–522
  259. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol. 2001;12:1643–1649
  260. Wargin WA, Lucas VS. The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol. 1994;21:21–27
  261. Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, Barra Y, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res. 1993;53:5121–5126
  262. Yao D, Ding S, Burchell B, Wolf CR, Friedberg T. Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther. 2000;294:387–395
  263. Groninger E, Meeuwsen-de BT, Koopmans P, Uges D, Sluiter W, Veerman A, et al. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res. 2002;52:113–118
  264. Crom WR, de Graaf SS, Synold T, Uges DR, Bloemhof H, Rivera G, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr. 1994;125:642–649
  265. Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, Uges DR, Kamps WA, de Graaf SS. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol. 1999;44:203–209
  266. Plasschaert SL, Groninger E, Boezen M, Kema I, de Vries EG, Uges D, et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther. 2004;76:220–229
  267. Groninger E, Meeuwsen-de BT, Koopmans P, Uges D, Sluiter W, Veerman A, et al. Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG). Eur J Cancer. 2005;41:98–103
  268. Lonnerholm G, Frost BM, Abrahamsson J, Behrendtz M, Castor A, Forestier E, et al. Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. Br J Haematol. 2008;142:616–621
  269. Frost BM, Lonnerholm G, Koopmans P, Abrahamsson J, Behrendtz M, Castor A, et al. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr. 2003;92:551–557
  270. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res. 2005;11:8097–8104
  271. Hurwitz CA, Relling MV, Weitman SD, Ravindranath Y, Vietti TJ, Strother DR, et al. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. J Clin Oncol. 1993;11:2324–2329
  272. Lesser GJ, Grossman SA, Eller S, Rowinsky EK. The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemother Pharmacol. 1995;37:173–178
  273. Hayashi RJ, Blaney S, Sullivan J, Weitman S, Vietti T, Bernstein ML. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol. 2003;25:539–542
  274. Woo MH, Relling MV, Sonnichsen DS, Rivera GK, Pratt CB, Pui CH, et al. Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res. 1999;5:543–549
  275. Doz F, Gentet JC, Pein F, Frappaz D, Chastagner P, Moretti S, et al. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. Br J Cancer. 2001;84:604–610
  276. Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, et al. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children’s Oncology Group study. Pediatr Blood Cancer. 2008;50:788–792
  277. van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat. 2008;11:77–98
  278. Franklin JL, Seibel NL, Krailo M, Fu C, Adamson PC, Reaman G. Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: a Children’s Oncology Group report. Pediatr Blood Cancer. 2008;50:533–536
  279. Seibel NL, Blaney SM, O’Brien M, Krailo M, Hutchinson R, Mosher RB, et al. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children’s Cancer Group trial. Clin Cancer Res. 1999;5:733–737
  280. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002;3:430–440
  281. Pommier Y, Goldwasser F. Topoisomerase II Inhibitors. In:  Chabner BA,  Longo DL editor. Cancer Chemotherapy & Biotherapy. Philadelphia: Lippincott Williams & Wilkins; 2006;p. 451–475
  282. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994;45:352–358
  283. Palle J, Britt-Marie F, Goran G, Marit H, Jukka K, Eva L, et al. Etoposide pharmacokinetics in children treated for acute myeloid leukemia. Anticancer Drugs. 2006;17:1087–1094
  284. Boos J, Real E, Schulze W, Wolff J, Euting T, Jurgens H. Investigation of the variability of etoposide pharmacokinetics in children. Int J Clin Pharmacol Ther Toxicol. 1992;30:495–497
  285. Kato Y, Nishimura S, Sakura N, Ueda K. Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. Pediatr Int. 2003;45:74–79
  286. Eksborg S, Soderhall S, Frostvik-Stolt M, Lindberg A, Liliemark E. Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children. Anticancer Drugs. 2000;11:237–241
  287. Veal GJ, Cole M, Errington J, Pearson AD, Gerrard M, Whyman G, et al. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer Chemother Pharmacol. 2010;65:1057–1066
  288. Lowis SP, Pearson AD, Newell DR, Cole M. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res. 1993;53:4881–4889
  289. Creaven PJ. The clinical pharmacology of VM26 and VP16–213. A brief overview. Cancer Chemother Pharmacol. 1982;7:133–140
  290. Evans WE, Sinkule JA, Crom WR, Dow L, Look AT, Rivera G. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16–213) in children with cancer. Cancer Chemother Pharmacol. 1982;7:147–150
  291. Sinkule JA, Stewart CF, Crom WR, Melton ET, Dahl GV, Evans WE. Teniposide (VM26) disposition in children with leukemia. Cancer Res. 1984;44:1235–1237
  292. D’Incalci M, Farina P, Sessa C, Mangioni C, Conter V, Masera G, et al. Pharmacokinetics of VP16–213 given by different administration methods. Cancer Chemother Pharmacol. 1982;7:141–145
  293. Herben VM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet. 1996;31:85–102
  294. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos. 1992;20:706–713
  295. Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol. 1996;14:1504–1511
  296. Blaney SM, Phillips PC, Packer RJ, Heideman RL, Berg SL, Adamson PC, et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996;78:527–531
  297. Rosing H, Herben VM, van Gortel-van Zomeren DM, Hop E, Kettenes-van den Bosch JJ, ten Bokkel Huinink WW, et al. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemother Pharmacol. 1997;39:498–504
  298. Rosing H, van Zomeren DM, Doyle E, Bult A, Beijnen JH. O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan. Anticancer Drugs. 1998;9:587–592
  299. Herben VM, Schoemaker E, Rosing H, van Zomeren DM, ten Bokkel Huinink WW, Dubbelman R, et al. Urinary and fecal excretion of topotecan in patients with malignant solid tumours. Cancer Chemother Pharmacol. 2002;50:59–64
  300. Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJ. An overview of the clinical pharmacology of topotecan. Semin Oncol. 1997;24:S5
  301. Wagner S, Erdlenbruch B, Langler A, Gnekow A, Kuhl J, Albani M, et al. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. Cancer. 2004;100:1750–1757
  302. Athale UH, Stewart C, Kuttesch JF, Moghrabi A, Meyer W, Pratt C, et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol. 2002;20:88–95
  303. Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, et al. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 1993;53:1032–1036
  304. Daw NC, Santana VM, Iacono LC, Furman WL, Hawkins DR, Houghton PJ, et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol. 2004;22:829–837
  305. Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Seibel NL, et al. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children’s Cancer Group. Clin Cancer Res. 1999;5:3956–3962
  306. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol. 1994;12:539–543
  307. Santana VM, Furman WL, Billups CA, Hoffer F, Davidoff AM, Houghton PJ, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol. 2005;23:4039–4047
  308. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol. 1994;12:1946–1954
  309. Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol. 1996;18:352–361
  310. Stewart CF, Iacono LC, Chintagumpala M, Kellie SJ, Ashley D, Zamboni WC, et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol. 2004;22:3357–3365
  311. Panetta JC, Schaiquevich P, Santana VM, Stewart CF. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res. 2008;14:318–325
  312. Schaiquevich P, Panetta JC, Iacono LC, Freeman BB, Santana VM, Gajjar A, et al. Population pharmacokinetic analysis of topotecan in pediatric cancer patients. Clin Cancer Res. 2007;13:6703–6711
  313. Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res. 1990;50:6525–6528
  314. Rivory LP, Chatelut E, Canal P, Mathieu-Boue A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res. 1994;54:6330–6333
  315. Rosner GL, Panetta JC, Innocenti F, Ratain MJ. Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther. 2008;84:393–402
  316. 316. Pfizer Inc (2009): Investigator brochure Irinotecan. Pfizer Inc.
  317. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994;54:3723–3725
  318. Dodds HM, Haaz MC, Riou JF, Robert J, Rivory LP. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther. 1998;286:578–583
  319. Haaz MC, Rivory L, Riche C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res. 1998;58:468–472
  320. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998;101:847–854
  321. Thompson PA, Gupta M, Rosner GL, Yu A, Barrett J, Bomgaars L, et al. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children’s oncology group. Cancer Chemother Pharmacol. 2008;62:1027–1037
  322. Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2007;25:4622–4627
  323. Vassal G, Doz F, Frappaz D, Imadalou K, Sicard E, Santos A, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol. 2003;21:3844–3852
  324. Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res. 1983;43:4467–4469
  325. Hempel G, Flege S, Wurthwein G, Boos J. Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2002;49:133–141
  326. Eksborg S, Palm C, Bjork O. A comparative pharmacokinetic study of doxorubicin and 4’-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure. Anticancer Drugs. 2000;11:129–136
  327. Frost BM, Eksborg S, Bjork O, Abrahamsson J, Behrendtz M, Castor A, et al. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol. 2002;38:329–337
  328. Palle J, Frost BM, Peterson C, Gustafsson G, Hellebostad M, Kanerva J, et al. Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs. 2006;17:385–392
  329. Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, Ellis KJ, et al. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol. 2009;64:243–251
  330. Tan CT, Hancock C, Steinherz P, Bacha DM, Steinherz L, Luks E, et al. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. Cancer Res. 1987;47:2990–2995
  331. Dreyer ZE, Kadota RP, Stewart CF, Friedman HS, Mahoney DH, Kun LE, et al. Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237. Neuro Oncol. 2003;5:261–267
  332. Foye WO, Vajragupta O, Sengupta SK. DNA-binding specificity and RNA polymerase inhibitory activity of bis(aminoalkyl)anthraquinones and bis(methylthio)vinylquinolinium iodides. J Pharm Sci. 1982;71:253–257
  333. Lown JW, Hanstock CC, Bradley RD, Scraba DG. Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy. Mol Pharmacol. 1984;25:178–184
  334. Kharasch ED, Novak RF. Inhibition of adriamycin-stimulated microsomal lipid peroxidation by mitoxantrone and ametantrone, two new anthracenedione antineoplastic agents. Biochem Biophys Res Commun. 1982;108:1346–1352
  335. Blanz J, Mewes K, Ehninger G, Proksch B, Waidelich D, Greger B, et al. Evidence for oxidative activation of mitoxantrone in human, pig, and rat. Drug Metab Dispos. 1991;19:871–880
  336. Chiccarelli FS, Morrison JA, Cosulich DB, Perkinson NA, Ridge DN, Sum FW, et al. Identification of human urinary mitoxantrone metabolites. Cancer Res. 1986;46:4858–4861
  337. Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL. Disposition of mitoxantrone in cancer patients. Cancer Res. 1985;45:1879–1884
  338. Mondick JT, Gibiansky L, Gastonguay MR, Skolnik JM, Cole M, Veal GJ, et al. Population pharmacokinetic investigation of actinomycin-D in children and young adults. J Clin Pharmacol. 2008;48:35–42
  339. Veal GJ, Cole M, Errington J, Parry A, Hale J, Pearson AD, et al. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children’s Cancer Study Group Study. Clin Cancer Res. 2005;11:5893–5899
  340. Chen J, Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer. 2005;5:102–112
  341. Bennett WM, Pastore L, Houghton DC. Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure. Cancer Treat Rep. 1980;64:921–924
  342. Crooke ST, Luft F, Broughton A, Strong J, Casson K, Einhorn L. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer. 1977;39:1430–1434
  343. Yee GC, Crom WR, Lee FH, Smyth RD, Evans WE. Bleomycin disposition in children with cancer. Clin Pharmacol Ther. 1983;33:668–673
  344. Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, et al. Circulating plasma platinum more than 10years after cisplatin treatment for testicular cancer. Lancet. 2000;355:1075–1076
  345. Townsend DM, Tew KD, He L, King JB, Hanigan MH. Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity. Biomed Pharmacother. 2009;63:79–85
  346. Bin P, Boddy AV, English MW, Pearson AD, Price L, Tilby MJ, et al. The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a review. Anticancer Res. 1994;14:2279–2283
  347. Peng B, Tilby MJ, English MW, Price L, Pearson AD, Boddy AV, et al. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. Br J Cancer. 1997;76:1466–1473
  348. de Jongh FE, Verweij J, Loos WJ, de WR, de Jonge MJ, Planting AS, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol. 2001;19:3733–3739
  349. Veal GJ, Dias C, Price L, Parry A, Errington J, Hale J, et al. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clin Cancer Res. 2001;7:2205–2212
  350. Bues-Charbit M, Gentet JC, Bernard JL, Breant V, Cano JP, Raybaud C. Continuous infusion of high-dose cisplatin in children: pharmacokinetics of free and total platinum. Eur J Cancer Clin Oncol. 1987;23:1649–1652
  351. Peng B, English MW, Boddy AV, Price L, Wyllie R, Pearson AD, et al. Cisplatin pharmacokinetics in children with cancer. Eur J Cancer. 1997;33:1823–1828
  352. Loos WJ, de Jongh FE, Sparreboom A, de WR, van Boven-van Zomeren DM, Stoter G, et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol. 2006;24:1499–1506
  353. Goodisman J, Souid AK. Constancy in integrated cisplatin plasma concentrations among pediatric patients. J Clin Pharmacol. 2006;46:443–448
  354. Veal GJ, Errington J, Tilby MJ, Pearson AD, Foot AB, McDowell H, et al. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. Br J Cancer. 2007;96:725–731
  355. Chatelut E, Boddy AV, Peng B, Rubie H, Lavit M, Dezeuze A, et al. Population pharmacokinetics of carboplatin in children. Clin Pharmacol Ther. 1996;59:436–443
  356. Newell DR, Pearson AD, Balmanno K, Price L, Wyllie RA, Keir M, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children’s Cancer Study Group. J Clin Oncol. 1993;11:2314–2323
  357. Picton SV, Keeble J, Holden V, Errington J, Boddy AV, Veal GJ. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. Cancer Chemother Pharmacol. 2009;63:749–752
  358. Tonda ME, Heideman RL, Petros WP, Friedman HS, Murry DJ, Rodman JH. Carboplatin pharmacokinetics in young children with brain tumors. Cancer Chemother Pharmacol. 1996;38:395–400
  359. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6:1205–1218
  360. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002;1:227–235
  361. Fouladi M, Blaney SM, Poussaint TY, Freeman BB, McLendon R, Fuller C, et al. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer. 2006;107:2291–2297
  362. Johnson TN. Modelling approaches to dose estimation in children. Br J Clin Pharmacol. 2005;59:663–669
  363. Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet. 2008;47:231–243

PII: S0305-7372(11)00059-4

doi: 10.1016/j.ctrv.2011.03.005

Cancer Treatment Reviews
Volume 38, Issue 1 , Pages 3-26 , February 2012

Article Tools

* Image Usage & Resolution